Dyne Therapeutics, Inc (DYN) FinancialsDYNDyne Therapeutics, Inc

Evaluating the bottom line, Dyne Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -81.57%, provide a clear picture of how effectively DYN converts its operational activities into shareholder value.

In the context of the broader market, DYN competes directly with industry leaders such as EWTX and ELVN. With a market capitalization of $4.80B, it holds a leading position in the sector. When comparing efficiency, DYN's gross margin of N/A stands against EWTX's N/A and ELVN's N/A. Such benchmarking helps identify whether Dyne Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Dyne Therapeutics reported a Q2 2026 net loss of $178.56 million, a 61% increase from the previous year, and a diluted EPS of -$1.08, missing estimates by $0.33. The company has a current ratio of 12.02, indicating strong liquidity, but it also has a negative P/E ratio of -9.01, reflecting ongoing losses.